chronic%20pelvic%20pain%20in%20women
CHRONIC PELVIC PAIN IN WOMEN
Chronic pelvic pain (CPP) is a persistent, distressing, & severe pain of >6 month duration.
It occurs intermittently, cyclically, or situationally.
Localized to the pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back, or the buttocks.
It is severe enough to cause functional disability or need medical care.
In women, CPP is not restricted to intercourse or menstruation & is not associated w/ pregnancy.
It is a symptom w/ a number of contributory factors & not a diagnosis; pathophysiology is complex & not well understood.
It is assumed that in the development of chronic pain, the nervous system is affected among others by inflammatory & chemical mediators & hormones.
A complex problem that is both multifactorial & multidimensional.

Surgical Intervention

  • Eg Adhesiolysis, hysterectomy, neurectomy
  • The symptomatic effect of surgical procedures for chronic pelvic pain (CPP) relies on the modulation or interruption of the pelvic neural pain transmission
  • Often successful if a related pathological finding is believed to be the possible cause of the symptoms even at the clinical stage

Laparoscopy

  • If a pelvic abnormality is suspected, laparoscopy is performed to confirm diagnosis and to treat contributing conditions (endometriosis, adhesions or both)
  • The mainstay of both diagnosis and surgical treatment of chronic pelvic pain (CPP) in women

Neuroablation

  • Eg Chemical neuroablation, radiofrequency thermocoagulation, pulsed or cooled radiofrequency, cryoneurolysis
  • Used for abdominal wall or pelvic floor neuralgia, it directly destroys neural tissue or alters neural conduction
  • More studies are needed before this can be recommended 
Transurethral Resection (Coagulation and Laser)
  • May be considered in patients with bladder pain syndrome type 3C if conventional treatments are ineffective
  • Reports suggest that transurethral laser results in prolonged alleviation of pain and urgency 
Open Surgery
  • Should only be considered for patients with bladder pain syndrome after all other therapies have failed
  • Some reports suggest that cystectomy with ileal conduit formation or supratrigonal cystectomy with bladder augmentation may provide relief from bladder pain
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.